Streetbeat News

BOLD

Boundless Bio Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

1.86

Mkt cap

39M

Volume

72K

High

1.90

P/E Ratio

-0.64

52-wk high

15.24

Low

1.76

Div yield

N/A

52-wk low

1.76

Boundless Bio has appointed Dr. Robert Doebele as its new Chief Medical Officer. Dr. Doebele brings over 15 years of experience in oncology drug development and has served as a Chief Medical Officer and clinical researcher at leading cancer centers.

Portfolio Pulse from

February 03, 2025 | 3:15 pm

The Russell 2000 Index, representing small-cap stocks, has risen by 0.4% in the first week of 2025, suggesting the 'January Effect' is gaining momentum.

Portfolio Pulse from

January 09, 2025 | 3:15 pm

Boundless Bio, Inc. (BOLD) has experienced a significant decline of 19.52% over the past four weeks. However, the stock is now in oversold territory, and Wall Street analysts are raising earnings estimates, suggesting a potential trend reversal.

Portfolio Pulse from

November 25, 2024 | 3:45 pm

Boundless Bio announced that Jami Rubin has stepped down as CFO. The company does not plan to hire a successor immediately, with David Hinkle, Senior Vice President, Finance and Controller, taking over finance operations.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 12:10 pm

Leerink Partners analyst Michael Cherny initiates coverage on Boundless Bio (NASDAQ:BOLD) with an Outperform rating and a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 7:11 pm

Guggenheim analyst Yige Guo initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Buy rating and a price target of $24.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:18 am

Piper Sandler analyst Joseph Catanzaro has initiated coverage on Boundless Bio (NASDAQ:BOLD) with an Overweight rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 9:20 am

Trading for IPO Security was halted but has now resumed as of 10:10:00 AM ET. This update indicates that the security is once again available for trading and quotation.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:10 pm

Boundless Bio has priced its IPO at $16 per share, offering 6.25M shares with expected gross proceeds of $100M. The stock, under the ticker 'BOLD', is set to begin trading on the Nasdaq Global Select Market on March 28, 2024, with the offering closing on April 2, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 6:57 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.